Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immunotech Biopharm Ltd ( (HK:6978) ) just unveiled an update.
Immunotech Biopharm Ltd has rescheduled its 2026 annual general meeting, moving it forward from 22 May to 30 April due to administrative reasons. The company confirmed that all previously announced AGM-related information remains unchanged apart from the revised date.
To align with the new AGM timetable, the book closure period will now run from 27 April to 30 April, during which share transfers will not be registered. Only shareholders on record as of 30 April will be eligible to attend and vote, ensuring clarity for investors and maintaining orderly governance procedures.
The most recent analyst rating on (HK:6978) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Immunotech Biopharm Ltd stock, see the HK:6978 Stock Forecast page.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a Cayman Islands-incorporated biopharmaceutical company listed on the Hong Kong Stock Exchange under stock code 6978. The company operates in the biotech and pharmaceutical sector, focusing on the research, development and commercialization of innovative therapies for the healthcare market.
Average Trading Volume: 304,807
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.68B
See more insights into 6978 stock on TipRanks’ Stock Analysis page.